Archives

Categories

About

Subscribe to this blog's feed
Add me to your TypePad People list

Copyright notice

  • TNFMedicine.com © 2007 Edward Lewis Tobinick MD, A Medical Corporation. All Rights Reserved.

Disclaimer

  • The views expressed in this blog are my personal thoughts and opinions. I maintain this blog for my own use, to categorize important medical information for myself as it develops. Posts are for informational and educational purposes only. This blog does not constitute medical advice, and none of its posts should be interpreted or relied on as such. This blog does not constitute a solicitation for business. No claims, promises, or guarantees about the accuracy of the information herein are made. Sending me an e-mail does not create a physician-patient relationship. Many of the posts herein contain abstracts and citations which are publically available at www.pubmed.gov, the online medical article database from the National Library of Medicine(which has no affiliation with this site). Many of the posts contain information regarding off-label uses of biologic TNF antagonists. This website should not be interpreted to imply or explicitly make or propose any treatment recommendations. The off-label uses discussed on this website are uses which are, by definition, not FDA-approved. Therefore the safety and efficacy of these uses have not yet been confirmed nor endorsed by the FDA, and no recommendation regarding the use of these reported methods is inferred or implied by their inclusion on this website. Biologic TNF-anatagonists, such as etanercept, infliximab, and adalimumab can have serious adverse effects, such as death, infection, cytopenias, and may be associated with an increased risk of lymphoma, demyelinating disease, eye inflammation, and congestive heart failure. Medical consultation prior to their use is mandatory.

Patent Notice

  • The following U.S. patents have been issued to Edward Tobinick MD concerning selected uses of certain biologic TNF antagonists and other cytokine antagonists for selected neurological and related indications in humans: 6,015,557; 6,177,077; 6,379,666; 6,419,934; 6,419,944; 6,423,321; 6,471,961; 6,428,787; 6,537,549; 6,982,089. Also Australian patent 758,523. Additional U.S. and foreign patents are pending.

« Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice | Main | Long-lasting neuropathic pain induced by brachial plexus injury in mice: Role triggered by the pro-inflammatory cytokine, tumour necrosis factor alpha »

January 23, 2007

A review of antibody therapeutics and antibody-related technologies for oncology

Title A review of antibody therapeutics and antibody-related technologies for oncology.
Author(s) Scallon BJ, Snyder LA, Mark Anderson G, Chen Q, Yan L, Weiner LM, Nakada MT 
Institution Centocor, Malvern, PA 19355 Fox Chase Cancer Center.
Source J Immunother 2006 Jul-Aug; 29(4) :351-64.
Language eng
Pub Type(s) Journal Article
PubMed ID 16799330

Posted at 04:30 PM in Scientific articles citing author's articles |

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83421064353ef00d8353ce03453ef

Listed below are links to weblogs that reference A review of antibody therapeutics and antibody-related technologies for oncology:

Comments

The comments to this entry are closed.